Eva Barnett
Fortuna: 11 M $ al 31/05/2026
Fortuna: 11 M $ al 31/05/2026
Eva Renee Barnett formerly worked at Immunovant, Inc., as Chief Financial & Accounting Officer from 2021 to 2025, Eli Lilly & Co., as Chief Financial Officer-Austria & Switzerland from 2011 to 2012, and AbleTo, Inc., as Chief Integration Officer in 2021.
Ms. Barnett received her undergraduate degree from DePauw University and Masters Business Admin degree from Harvard Business School.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
IMMUNOVANT INC 0,16 % | 13/06/2025 | 327.119 ( 0,16 % ) | 11 M $ | 31/05/2026 |
| Empresas | Cargo | Fin |
|---|---|---|
| IMMUNOVANT, INC. | Director Financiero/CFO | 20/04/2025 |
AbleTo, Inc.
AbleTo, Inc. Medical/Nursing ServicesHealth Services Provides online therapy and coaching services for mental health conditions | Director Financiero/CFO | 01/03/2018 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 01/08/2012 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 5 |
|---|---|
Eli Lilly & Co.
Eli Lilly & Co. Pharmaceuticals: MajorHealth Technology Manufactures, wholesales and markets pharmaceutical products | Health Technology |
AbleTo, Inc.
AbleTo, Inc. Medical/Nursing ServicesHealth Services Provides online therapy and coaching services for mental health conditions | Health Services |
DePauw University
DePauw University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard Business School
Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Immunovant, Inc.
Immunovant, Inc. BiotechnologyHealth Technology Develops restorative therapies for autoimmune diseases | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.